GenomeConnect, the NIH-funded Clinical Genome Resource (ClinGen) patient registry, engages patients in data sharing to support the goal of creating a genomic knowledge base to inform clinical care and research. Participant self-reported health information and genomic variants from genetic testing reports are curated and shared with public databases, such as ClinVar. There are four primary benefits of GenomeConnect: (1) sharing novel genomic data-47.9% of variants were new to ClinVar, highlighting patients as a genomic data source; (2) contributing additional phenotypic information-of the 52.1% of variants already in ClinVar, GenomeConnect provided enhanced case-level data; (3) providing a way for patients to receive variant classification updates if the reporting laboratory submits to ClinVar-97.3% of responding participants opted to receive such information and 13 updates have been identified; and (4) supporting connections with others, including other participants, clinicians, and researchers to enable the exchange of information and support-60.4% of participants have opted to partake in participant matching. Moving forward, ClinGen plans to increase patient-centric data sharing by partnering with other existing patient groups. By engaging patients, more information is contributed to the public knowledge base, benefiting both patients and the genomics community.
F I G U R E 1 GenomeConnect participation process. The figure depicts the steps GenomeConnect participants engage in while enrolling in the registry, data collection methods, and ongoing engagement effort relies on data sharing, and, as a result, ClinGen actively collaborates with laboratories, researchers, clinicians, patients, and other stakeholders to enable submission of genomic data to the publicly available ClinVar database, a repository of human genomic variants and their relationship to human health within the National Center for Biotechnology Information (NCBI) at the NIH (Landrum et al., 2014 (Landrum et al., , 2016 (Landrum et al., , 2018 Rehm, 2017 ; https://www.ncbi.nlm.nih.gov/clinvar/).
GENOMECONNECT
GenomeConnect, the ClinGen online patient registry, was developed and launched in October 2014 to engage patients in data-sharing efforts (Kirkpatrick et al., 2015;  https://genomeconnect.org). Specifically, GenomeConnect was created to capture individual-level phenotype information, vital to the variant interpretation process, from the patients themselves. Genomic testing laboratories often do not have detailed phenotype information regarding patients in whom rare variants are found. Access to this detailed phenotype information can greatly inform the interpretation process (Riggs, Jackson, Miller, & Van Vooren, 2012) .
Participation in GenomeConnect is open to anyone who has
had genetic testing regardless of genetic test results or diagnosis.
Participants consent to have their genetic and health information de-identified and shared with public databases, such as ClinVar.
Health information is collected via participant-completed surveys and importantly, genomic data are reviewed and curated from participants' uploaded genetic test reports by genetic counseling staff to ensure accuracy and consistency of genomic data (Kirkpatrick et al., 2015;  Figure 1).
As of April 2018, 1,601 participants from 32 countries have enrolled in GenomeConnect. Participants report learning about GenomeConnect in varied ways; the most common sources of referral are healthcare providers (29.4%%, n = 471/1,601) and information on genetic testing reports (27.1%, n = 434/1,601). GenomeConnect participants range in age from less than 1 year to 91 years old. Sixty percent (60.5%, n = 968/1,601) of participants identified as female, 37.5%
(n = 601/1,601) identified as male, 0.6% (n = 10/1,601) identified as something else (e.g., female to male (FTM)/transman/transgender male, intersex, other), and 1.4% (n = 22/1,601) did not provide a response. The majority of participants underwent genetic testing to confirm a diagnosis (20.4%, n = 326/1,601), evaluate symptoms (42.7%, n = 684/1,601), or determine if they carry a familial variant (11.9%, n = 191/1,601). Healthy individuals who have undergone testing to be proactive about their health or to determine reproductive risks have also enrolled in the registry (4.6%, n = 74/1,601).
COLLECTION OF PARTICIPANT-PROVIDED PHENOTYPE DATA VIA HEALTH SURVEY
Phenotype information is collected through participant health surveys and shared using corresponding Human Phenotype Ontology (HPO) terms (Köhler et al., 2017; Robinson & Mundlos, 2010) . The GenomeConnect team collaborated with the ClinGen Phenotype working group to develop an initial health survey and describe HPO terms in patient-friendly language (Kirkpatrick et al., 2015) . Invited working group members included clinicians, laboratorians, and representatives from HPO and other phenotyping tools. A review of clinical intake and high-level HPO terms informed the structure of this general health survey, designed to serve as an overall "review of systems" for each GenomeConnect participant. For all survey questions, the associated medical term is provided along with example(s) or a patient-friendly description developed by members of the Phenotype working group. Appropriate HPO mappings were determined by the group and programmed into the survey so that survey responses automatically map to HPO terms on the back-end and can be exported using these structured identifiers. The current version of the GenomeConnect general health survey is available online and has been available for review and use since GenomeConnect's launch in 2014 (https://tinyurl.com/y9v29onh; Supporting Information Figure S1 ).
Other registries and research groups have adopted all or portions of this survey for use as a general health data collection tool including other registries on the same platform at GenomeConnect through Invitae and the Undiagnosed Disease Network.
For each general body system, the participant is asked whether or not they have any issues related to this system. If they answer "Yes," they are presented with a brief list of phenotypic features within that body system deemed by the ClinGen Phenotype working group to be potentially indicative of a genetic disorder. This list is purposefully brief and the survey uses branching logic in order to minimize time required to complete the survey. For example, if the participant answered "No" to the high-level question for a given body system (e.g., "Ears and/or Hearing"), they would not be presented with the follow-up questions related to that body system. Currently, the GenomeConnect survey has not been validated against data extracted from patients' electronic health records, but validation efforts and further survey modifications are being pursued through a Patient-Centered Outcomes Research Institute funded collaboration (https://tinyurl.com/ybl3eb5z).
Any concerns indicated on the initial survey can also be further detailed in subsequent subsurveys as needed (Kirkpatrick et al., 2015) .
For example, if the participant indicated that they had a history of cardiomyopathy, they may be invited to participate in a follow-up survey designed to learn more about the specific type, when and how it was diagnosed, treatment modalities, other risk factors, and outcomes. Additional surveys have been developed by the GenomeConnect team, in collaboration with ClinGen clinical domain working groups and expert panels, in an effort to collect phenotypic data that would aid their curation efforts (https://tinyurl.com/y89gbka9).
Surveys developed to date include cardiomyopathy, congenital heart defect, arrhythmia, and cancer surveys. Responses from these surveys are also mapped to HPO terms to allow for structured data sharing.
SUBMISSION OF PATIENT-DERIVED DATA TO CLINVAR
NCBI's ClinVar provides a publicly available database of the relationship between genomic variants and phenotypes. ClinVar is a database that relies on submissions from many groups, including clinical genetic testing and research laboratories, clinicians, locus-specific databases, OMIM R , GeneReviews TM , expert panels, and practice guidelines (Landrum et al., 2016) . ClinVar aggregates submitted interpretations of the clinical significance of variants and allows submitters to provide structured and free text supporting evidence (Landrum et al., 2014 This genomic and health data are submitted to ClinVar as a "phenotyping only" submission. This collection method is reserved for variants submitted to ClinVar that provide individual observations with phenotype data without an independent variant interpretation from the submitter (Landrum et al., 2018) . This distinct collection method highlights for the user the fact that these variants may also be submitted directly from the reporting laboratory (typically under the collection method "clinical testing"). The reporting laboratory name, that laboratory's reported interpretation, the report date, segregation data, and detailed phenotype terms are included in GenomeConnect's "phenotyping only" submissions. However, some of this information is not currently displayed in the ClinVar web display and is only available in the XML monthly data release 
FACILITATING VARIANT INTERPRETATION UPDATES
Of the variants previously submitted by the participant's reporting laboratory (n = 232), the classification on the participant's report was out of date compared to the laboratory's current ClinVar entry for 13 (5.6%) variants. In all instances, the reporting laboratory had reclassified the variant after the patient's results were reported. As detected by a laboratory has grown enormously, the ability of laboratories to provide timely updates to providers has already become unsustainable (Richards et al., 2015) . 
FACILITATING DISCREPANCY RESOLUTION
Of the genomic variants previously submitted by a laboratory other than the reporting institution, 41.3% (n = 107/259) had a major category difference in variant classification between the participant report and another submission. As shown in Inter-Laboratory Discrepancy Resolution group then encourages submitting laboratories with these discrepant interpretations to address major category discrepancies (Harrison et al., 2017) . GenomeConnect can provide additional participant phenotype data to inform these deliberations.
In conjunction with this working group, all variants with major category discrepancies between the GenomeConnect participant's report and other ClinVar submitters were reviewed (n = 107). From that review, 22 variants were prioritized for outlier reassessment (if at least one submitting laboratory submitted an interpretation that differed from the majority of other submitters). These laboratories were contacted by the working group and prompted to reassess the variants. Of the 22 variants, 13 had medically significant discrepancies (LP/P vs. LB/B/VUS) and nine were not medically significant (LB/B vs. VUS). Eight discrepancies were resolved completely and three were partially resolved. Those that were partially resolved initially had a majority of laboratories with concordant variant classifications and two or more laboratories with a differing interpretation. In these cases, one laboratory resolved their discrepancy with the majority of other submitters, but at least one other discrepancy remained (S.M. Harrison, personal communication, April 18, 2018) . Of the 11 discrepancies resolved or partially addressed, seven resulted in a classification update from the GenomeConnect participants' reporting laboratory.
These seven variant interpretation updates will be shared with participants that opted to receive them. In one instance to date, GenomeConnect participant data indicating the variant was de novo led to resolution of a medically significant discrepancy between two clinical laboratories.
FACILITATING MATCHMAKING
In addition to facilitating genomic data sharing, GenomeConnect also allows participants to connect with other stakeholders, including researchers, clinicians, and other patients and families. Within the registry, participants can search for others based on gene, disease, or U.S. state using the participant matching interface (Kirkpatrick et al., 2015 In addition to connecting participants within the registry, GenomeConnect also allows for matchmaking with external clinicians and researchers through Matchmaker Exchange (MME). MME is a federated network of rare disease datasets established to facilitate candidate gene matching (Philippakis et al., 2015; Sobreira et al., 2017) . Currently, GenomeConnect actively submits variants in genes of uncertain significance on behalf of our participants to MME through GeneMatcher (Sobreira, Schienttecatte, Valle, & Hamosh, 2015) , one of the connected nodes. To date, 14 of 16 submitted cases yielded potential matches. All submitters of potential matches were contacted by the GenomeConnect genetic counselors and, in three cases, researchers requested to connect directly with participants.
Matching across MME is currently limited to clinician and researcher-initiated cases. To ensure GenomeConnect participants also match with the patient-initiated cases from MyGene2 (University (Zurynski, Frith, Leonard, & Elliott, 2008 ClinGen is prioritizing engagement of groups that represent a disease area where ClinGen has existing gene and variant curation efforts (e.g.,
RASopathies and inborn errors of metabolism). Doing so will increase data available for curation efforts and can ultimately allow patients to receive updated variant interpretations that may be produced as a result. ClinGen is working to pilot these data-sharing partnerships with several existing registries and advocacy groups interested in creating a disease-specific registry.
CONCLUSIONS
Broad data sharing of genotypic and phenotypic information is needed to inform variant interpretation, gene-disease relationships, and actionability of genomic information to ultimately improve patient care. Through GenomeConnect and collaborations with external patient groups, ClinGen is partnering with patients in data-sharing efforts. GenomeConnect's experience to date highlights the utility of patient-shared data and the ways in which increasing patient engagement in genomic data sharing benefits both patients and the genomics community. Inter-Laboratory Discrepancy Resolution group and participating laboratories for their discrepancy resolution efforts. Finally, we would like to acknowledge our GenomeConnect participants that make this work possible.
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